KMT2A and acute myeloid leukemia: To generate a population of mice with established disease for molecular characterization, recipients of MLL1-ELL–transduced, syngeneic bone marrow were sacrificed upon development of AML (circulating myeloid blasts of >30% of white blood cells or 15,000/mm3), and bone marrow was transplanted into secondary recipients.